Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5426179 | 1.00 | NR1H2 (0.56) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL5414571 | 1.00 | NR1H2 (0.56) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL3551512 | 1.00 | NR1H2 (0.56) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL3551509 | 1.00 | NR1H2 (0.56) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL15511211 | 0.85 | NR1H2 (0.56) | NR1H2ALDH1A1CHRM2CHRM1CHRM3 | |
| SCHEMBL22557668 | 0.85 | NR1H2 (0.56) | NR1H2ALDH1A1CHRM2CHRM1CHRM3 | |
| SCHEMBL15511259 | 0.85 | NR1H2 (0.56) | NR1H2ALDH1A1CHRM2CHRM1CHRM3 | |
| SCHEMBL5416595 | 0.83 | GPR119 (0.41) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL515486 | 0.81 | NR1H2 (0.62) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL621267 | 0.81 | NR1H2 (0.62) | NR1H2MEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834014-B2 | Parkinson's disease; [2-(7-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)-octahydro-pyrido[1,2-a]pyrazin-7-yl]-methanol; | BIOGEN IDEC MA INC. (US) | 2010-11-16 | — | — | US | disclosed |
| EP-1633756-B1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | BIOGEN IDEC INC (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20070173505-A1 | A2a adenosine receptor antagonists | BIOGEN IDEC MA INC. | 2007-07-26 | — | — | US | disclosed |
| EP-1761267-A1 | DIAZABICYCLIC HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-03-14 | — | — | EP | disclosed |
| EP-1633756-A2 | A2A ADENOSINE RECEPTOR ANTAGONISTS | Biogen Idec MA Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2006000914-A1 | DIAZABICYCLIC HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050282811-A1 | Diazabicyclic histamine-3 receptor antagonists | PFIZER INC | 2005-12-22 | — | — | US | disclosed |
| WO-2004092173-A2 | A2A ADENOSINE RECEPTOR ANTAGONISTS | BIOGEN IDEC MA INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| EP-1070065-B1 | AZABICYCLIC 5HT1 RECEPTOR LIGANDS | PFIZER PROD INC (US) | 2003-09-03 | — | — | EP | disclosed |
| EP-0646116-B1 | PROCESS AND INTERMEDIATES FOR BIS-AZA-BICYCLIC ANXIOLYTIC AGENTS | PFIZER (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1993025552-A1 | PROCESS AND INTERMEDIATES FOR BIS-AZA-BICYCLIC ANXIOLYTIC AGENTS | PFIZER INC. (US) | 1993-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173505-A1 | A2a adenosine receptor antagonists | ADORA2A, ADORA1, ADORA3 | NR1H2 1812/4885MEN1 3969/4885ALDH1A1 357/4885 |
| US-20050282811-A1 | Diazabicyclic histamine-3 receptor antagonists | HRH3, HRH4, HRH2 | NR1H2 941/4885MEN1 2112/4885ALDH1A1 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.